GILD - Estimating The Potential Success Of Late Clinical Stage NASH Treatments
Editor's note: Seeking Alpha is proud to welcome Richelle Cutler-Strom as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
There is a worldwide epidemic of obesity and metabolic syndrome driving the need to find treatments for high cholesterol and nonalcoholic steatohepatitis ((NASH)), a non-alcoholic fatty liver disease ((NAFLD)). Currently, there is no approved drug for treating NASH, and the market for an effective treatment is huge.